ClassID:

95326

C07D451/14 - CPC Classification

Classification description:

Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Recent Application in this class:
#1
20260132143
2026-05-14

HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF

#2
20260042777
2026-02-12

PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF

#3
20250243171
2025-07-31

QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE

#4
20250145617
2025-05-08

SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF

#5
20250101016
2025-03-27

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#6
20240343718
2024-10-17

TREATMENT OF NEUROLOGICAL DISORDERS

#7
20240300937
2024-09-12

Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors

#8
20240158389
2024-05-16

Pyrimidine compound as JAK kinase inhibitor

#9
20230391789
2023-12-07

Bicyclic compounds as kinase modulators, methods and uses thereof

#10
20230257365
2023-08-17

SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS

#11
20230069804
2023-03-02

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#12
20230068499
2023-03-02

Methods and compositions for modulating splicing

#13
20230067064
2023-03-02

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#14
20230059865
2023-02-23

Methods and compositions for modulating splicing

#15
20230054781
2023-02-23

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#16
20230009712
2023-01-12

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#17
20220403383
2022-12-22

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#18
20220402908
2022-12-22

CXCR6 INHIBITORS AND METHODS OF USE

#19
20220396573
2022-12-15

Pyrimidine compound as JAK kinase inhibitor

#20
20220135551
2022-05-05

Treatment of neurological disorders

#21
20220048902
2022-02-17

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

#22
20220033394
2022-02-03

COMPOUNDS FOR THE TREATMENT OF PAIN

#23
20210387969
2021-12-16

Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists

#24
20210309668
2021-10-07

Bicyclic compounds as kinase modulators, methods and uses thereof

#25
20210292316
2021-09-23

Compounds for the treatment of cancer

#26
20210221805
2021-07-22

SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF

#27
20210214349
2021-07-15

Pyrimidine compound as JAK kinase inhibitor

#28
20210171519
2021-06-10

Methods and compositions for modulating splicing

#29
20210101893
2021-04-08

Pharmaceutical compounds

#30
20210040067
2021-02-11

Pharmaceutical compounds

#31
20210002271
2021-01-07

Pharmaceutical compounds

#32
20200369660
2020-11-26

Pyrimidine compound as JAK kinase inhibitor

#33
20200277289
2020-09-03

Methods and compositions for modulating splicing

#34
20200247799
2020-08-06

Methods and compositions for modulating splicing

#35
20200224199
2020-07-16

Methods and compositions for modulating splicing

#36
20200223847
2020-07-16

Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds

#37
20200140430
2020-05-07

Pyrimidine compound as JAK kinase inhibitor

#38
20200123149
2020-04-23

Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

#39
20200046709
2020-02-13

Pyrimidine compounds as JAK kinase inhibitors

#40
20200002328
2020-01-02

Pharmaceutical compounds

#41
20190389849
2019-12-26

Pharmaceutical compounds

#42
20190389833
2019-12-26

Pyridine-2-yl pyridinium compound and method of using same

#43
20190337911
2019-11-07

Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them

#44
20190322686
2019-10-24

Compound and pharmacologically acceptable salt thereof

#45
20190284178
2019-09-19

TREATMENT OF NEUROLOGICAL DISORDERS

#46
20190276437
2019-09-12

Pharmaceutical compounds

#47
20190241555
2019-08-08

Pyrimidine compound as JAK kinase inhibitor

#48
20190127364
2019-05-02

Pyrimidine compound as JAK kinase inhibitor

#49
20190119237
2019-04-25

Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them

#50
20190100518
2019-04-04

INDOLE STRUCTURE-SELECTIVE CROSSLINKING AGENT AND COMPOSITE IN WHICH SAME IS USED

#51
20190047980
2019-02-14

Heteroarylbenzimidazole compounds

#52
20190002457
2019-01-03

Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

#53
20180370971
2018-12-27

9′-Aza[3,9′-bi(bicyclo[3.3.1]nonan)]-3′-one and preparation thereof

#54
20180362507
2018-12-20

Pharmaceutical compounds

#55
20180353434
2018-12-13

Nucleic acid-containing lipid nanoparticles

#56
20180318270
2018-11-08

Selective High Affinity Alpha3Beta4 Nicotinic Acetycholine Receptor Antagonists

#57
20180303836
2018-10-25

Pyrimidine compounds as JAK kinase inhibitors

#58
20180244653
2018-08-30

Selective alpha-7 nicotinic receptor agonists and methods for making and using them

#59
20180148449
2018-05-31

Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof

#60
20180086739
2018-03-29

PLK4 inhibitors

#61
20180002327
2018-01-04

Heteroaryl compounds as IRAK inhibitors and uses thereof

#62
20170313713
2017-11-02

Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

#63
20170233345
2017-08-17

SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF

#64
20170174710
2017-06-22

Compounds that are S1P modulating agents and/or ATX modulating agents

#65
20170015660
2017-01-19

Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

#66
20160200726
2016-07-14

Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative

#67
20160159785
2016-06-09

Substituted-quinoxaline-type piperidine compounds and the uses thereof

#68
20160145252
2016-05-26

Heteroaryl compounds as IRAK inhibitors and uses thereof

#69
20160068556
2016-03-10

Targeted nitroxide agents

#70
20160024074
2016-01-28

PROCESS FOR EXTRACTING THE ALKALOID FRACTION OF RHODOPHIALA BIFIDA (HERB.) TRAUB AND USES THEREOF

#71
20160009717
2016-01-14

Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators

#72
20160002203
2016-01-07

Quinazolin-4(3H)-one-type piperidine compounds and uses thereof

#73
20150361060
2015-12-17

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM

#74
20150239882
2015-08-27

NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES

#75
20150183741
2015-07-02

Compounds that are S1P modulating agents and/or ATX modulating agents

#76
20150148541
2015-05-28

Nicotinic acetylcholine receptor modulators

#77
20150141643
2015-05-21

Substituted-quinoxaline-type piperidine compounds and the uses thereof

#78
20150031887
2015-01-29

9-azanoradamantane N—oxyl compound and method for producing same, and organic oxidation catalyst and method for oxidizing alcohols using 9-azanoradamantane N—oxyl compound

#79
20150018556
2015-01-15

Process for preparing tiotropium bromide

#80
20140187544
2014-07-03

Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators

#81
20140135306
2014-05-15

Hydroxy substituted isoquinolinone derivatives

#82
20140031330
2014-01-30

Aryl sultam derivatives as RORc modulators

#83
20140018317
2014-01-16

Targeted nitroxide agents

#84
20130310366
2013-11-21

5-HTreceptor modulators, methods of making, and use thereof

#85
20130274265
2013-10-17

Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators

#86
20120310005
2012-12-06

Method for producing 2-azaadamantane

#87
20120245195
2012-09-27

Monohydrate of azaadamantane derivatives

#88
20120219641
2012-08-30

5-HTreceptor modulators, methods of making, and use thereof

#89
20120214817
2012-08-23

Urotensin II receptor antagonists

#90
20120108575
2012-05-03

2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain

#91
20120020881
2012-01-26

Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes

#92
20110212938
2011-09-01

Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119

#93
20110178119
2011-07-21

Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase

#94
20110178090
2011-07-21

Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators

#95
20110178075
2011-07-21

INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF

#96
20110172264
2011-07-14

Nicotinic acetylcholine receptor modulators

#97
20110136854
2011-06-09

NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

#98
20110136824
2011-06-09

Urotensin II receptor antagonists

#99
20110118305
2011-05-19

COMPOUNDS

#100
20110003802
2011-01-06

Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase

#101
20100311977
2010-12-09

Method for producing 2-azaadamantane

#102
20100305089
2010-12-02

Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives

#103
20100291020
2010-11-18

Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors

#104
20100216726
2010-08-26

Substituted-quinoxaline-type piperidine compounds and the uses thereof

#105
20100210838
2010-08-19

Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity

#106
20100204264
2010-08-12

Polymorphic form of Granisetron base, methods for obtaining it and formulation containing it

#107
20100166839
2010-07-01

NON PEPTIDIC RENIN INHIBITORS NITRODERIVATIVES

#108
20100113405
2010-05-06

METHYLINDAZOLE MODULATORS OF 5-HT3 RECEPTORS

#109
20100081680
2010-04-01

N-sulfonamido polycyclic pyrazolyl compounds

#110
20100048614
2010-02-25

Therapeutic uses of bicyclic ligands of sigma 2 receptor

#111
20100022519
2010-01-28

Compounds comprising heterocyclic-substituted piperidine for treating pain

#112
20090298809
2009-12-03

5-HTreceptor modulators, methods of making, and use thereof

#113
20090275610
2009-11-05

TRICYCLIC OPIOID MODULATORS

#114
20090227576
2009-09-10

2-alkylbenzoxazole carboxamides as 5HT3 modulators

#115
20090227570
2009-09-10

2-aminoquinolines

#116
20090124807
2009-05-14

Intermediate compounds useful to prepare dolasetron

#117
20090118326
2009-05-07

Nicotinic acetylcholine receptor modulators

#118
20090118232
2009-05-07

Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

#119
20090076061
2009-03-19

MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS

#120
20080242696
2008-10-02

CRYSTALLINE GRANISETRON BASE AND PRODUCTION PROCESS THEREFOR

#121
20080214601
2008-09-04

2-alkylbenzoxazole carboxamides as 5-HTmodulators

#122
20080167336
2008-07-10

Azaadamantane derivatives and methods of use

#123
20080161343
2008-07-03

Sigma 2 receptor ligands and therapeutic uses therefor

#124
20080161310
2008-07-03

Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity

#125
20080108609
2008-05-08

Benzoxazole carboxamides for treating CINV and IBS-D

#126
20080090828
2008-04-17

N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines

#127
20080090817
2008-04-17

Bridged N-cyclic sulfonamido inhibitors of gamma secretase

#128
20080076755
2008-03-27

Anti-inflammatory A-aminocyclolactam compounds

#129
20080045539
2008-02-21

Fused bicycloheterocycle substituted azabicyclic alkane derivatives

#130
20070293531
2007-12-20

Muscarinic Acetycholine Receptor Antagonists

#131
20070232641
2007-10-04

Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

#132
20070213359
2007-09-13

BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF

#133
20070203219
2007-08-30

Production of dolasetron

#134
20070203177
2007-08-30

Forms of dolasetron mesylate and processes for their preparation

#135
20070203176
2007-08-30

Crystalline forms of dolasetron base and processes for preparation thereof

#136
20070203175
2007-08-30

Productioin of dolasetron

#137
20070197580
2007-08-23

5-HT3 receptor antagonists and methods of use

#138
20070197530
2007-08-23

Amido compounds and their use as pharmaceuticals

#139
20070196270
2007-08-23

Compounds As Ccri Antagonists

#140
20070191391
2007-08-16

Urotensin II receptor antagonists

#141
20070054912
2007-03-08

Modulators of acetylcholine receptors

#142
20070049612
2007-03-01

Bridged N-cyclic sulfonamido inhibitors of gamma secretase

#143
20060287297
2006-12-21

Tricyclic opioid modulators

#144
20060183769
2006-08-17

Benzoxazole carboxamides for treating CINV and IBS-D

#145
20060166962
2006-07-27

N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines

#146
20060135504
2006-06-22

N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines

#147
20050250808
2005-11-10

Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

#148
20050203104
2005-09-15

Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments

#149
20050192430
2005-09-01

Linker arms for nanocrystals and compounds thereof

#150
20050182088
2005-08-18

Modulators of acetylcholine receptors

#151
20050153973
2005-07-14

Compounds

#152
20050130981
2005-06-16

Compounds

#153
20050059712
2005-03-17

Acylsulfonamides as inhibitors of steroid sulfatase

#154
20050054664
2005-03-10

Anticholinergics, processes for preparing them and pharmaceutical composition containing them

#155
17502810
2022-05-10

Methods and compositions for modulating splicing